A Phase 2 interventional study of Paclitaxel and Bleomycin in Germ Cell Cancer Metastatic, sponsored by Blokhin's Russian Cancer Research Center. Recruiting at 1 site in Russia. Open to male participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Blokhin's Russian Cancer Research Center · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing paclitaxel in Testicular Neoplasms — 1 open to participants now, 1 under way, none of them phase 3. Paclitaxel · Testicular Neoplasms.
Among the 15 studies testing paclitaxel in Testicular Neoplasms, this one is the 3rd largest by planned enrollment, is the only one that started in 2024, is one of 9 in phase 2, and was the 15th registered.
295 studies on the registry are indexed under Testicular Neoplasms; 51 are open to participants now.
Browse Testicular Neoplasms studies →1 of the 15 studies testing paclitaxel in Testicular Neoplasms is open now, in 1 country.
By country, each count listing its studies:
Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 43 Testicular Neoplasms studies recruiting now, 26 (60%) set no upper age limit and 11 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 16 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 3
First in 1996; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 50 across 190 interventional studies indexed under Testicular Neoplasms.
Median enrollment 26 across the 15 interventional studies. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 15 has an industry lead sponsor. The 10 most frequent:
Blokhin's Russian Cancer Research Center is the lead sponsor of 34 studies on the registry; 17 are open to participants now.
Blokhin's Russian Cancer Research Center has 1 study filed under Testicular Neoplasms — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing paclitaxel in Testicular Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
GETUG-13 study has prospectively confirmed poor outcomes in advanced germ cell tumors (GCT) patients with unfavorable decrease of tumor markers after 1 cycle of BEP chemotherapy. There is an unmet medical need to improve outcomes in this subset of patients, however the dose-dense regimen proposed in the above-mentioned trial cannot be implemented in routine clinical practice. T-BEP regimen may have advantage over the traditional BEP regimen as first-line therapy for poor-risk GCT Treatment escalation with T-BEP regimen may be an effective and tolerable therapeutic option for advanced GCT patients with unfavorable tumor markers decline.
Screening procedures:
Treatment:
After registration patients will receive first cycle of standard BEP chemotherapy: cisplatin 20 mg/m² IV days 1-5, etoposide 100 mg/m² IV days 1-5, bleomycin 30 mg IV days 1, 8 and 15 OR days 1, 3 and 5 + G-CSF 5 mcg/kg subcutaneous day 6, until post-nadir absolute neutrophil count ≥ 1.0 x 10\^9. In patients with ultra-high level of tumor markers and/or poor performance status (eg, ECOG3-4) administration of a disease stabilizing chemotherapy first cycle of chemotherapy is allowed.
After 1st cycle of BEP tumor markers will be reassessed between days 18 and 21, and their kinetics will be centrally calculated (App: Tumor marker decline calculator poor-risk GCT - http://www.gustaveroussy.fr/calculation-tumor/NSGCT.html).
Patients with favorable tumor markers for both AFP and B-HCG decline will receive three subsequent cycles of BEP.
Patients with unfavorable tumor markers decline will be centrally randomized stratified by center, mediastinum primary tumor, 1st cycle in stabilizing schedule, and brain metastasis to the following arms.
Patients with complete response radiological and marker response after completion of chemotherapy to be followed without additional therapy (surveillance according to guidelines). Patients with radiographically detectable residual masses (eg, retroperitoneal lymph nodes, mediastinal lymph nodes, lung metastases) ≥10 mm and normal STMs (partial remission with negative STMs) should undergo surgery with goal to remove all the residual disease. If the patient considered to have unresectable tumor or to be medically inoperable the treatment approach is to be selected individually.
Patients with viable GCTs in completely resected masses (except for mature teratoma) will be managed with 2 more cycles of EP or TIP chemotherapy.
Patients are following for at least 3 years according to the following schedule: once every 2 months for 2 years, once every 4 months in the third year, once every 6 months in the fourth year, and once every year after the fourth year. Surveillance includes a clinical examination, AFP, b-HCG, LDH, creatinine, blood count, and a CT scan of the initially involved sites every 4 months for 2 years, and then once yearly in the next 3 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Disease classified as poor prognosis according to IGCCCG criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive 3 cycles of T-BEP after the first cycle of the BEP regimen and unfavorable tumor marker decline, followed by standard of care surgery. Each cycle is 21 days.
Drug: Paclitaxel · Drug: Bleomycin · Drug: Etoposide · Drug: Cisplatin · Drug: G-CSF (Filgrastim)
Participants receive 3 cycles of BEP after the first cycle of the BEP regimen and unfavorable tumor marker decline, followed by standard of care surgery. Each cycle is 21 days.
Drug: Bleomycin · Drug: Etoposide · Drug: Cisplatin · Drug: G-CSF (Filgrastim)
Paclitaxel 175 mg/m\^2 IV infusion, Day 1, Q3W for 3 cycles in first line
Bleomycin sulfate 30 mg IV infusion, Days 1,3,5, Q3W for 4 cycles in first line
Etoposide 100 mg/m\^2 IV infusion, Days 1-5, Q3W for 4 cycles in first line
Also known as: VP-16
Cisplatin 20 mg/m\^2 IV infusion, Days 1-5, Q3W for 4 cycles in first line
G-CSF 5 mcg/kg subcutaneous, on Day 6, until post-nadir absolute neutrophil count ≥ 1.0 x 10\^9, Q3W for 4 cycles in first line
Also known as: Zarzio, Tevagrastim, Neupomax
1-year progression-free survival (PFS)
1-year PFS is defined as time from enrollment to disease progression or relapse or death due to any cause at 1 year (12-month PFS)
Time frame: Time from enrollment to disease progression or relapse or death due to any cause, or data cut-off date at 1 year, whichever occured first (up to ~60 months)
Overall Survival
OS is defined as time from enrollment to death due to any cause
Time frame: Time from enrollment to death due to any cause, or data cut-off date, whichever occurred first (up to ~60 months)
Complete response rate (CRS)
CRS is defined as normalization of tumor markers and no clinical or radiological evidence of disease
Time frame: Time from enrollment to completion of the 4th cycle of chemotherapy, disease progression, or death, whichever occurs first (up to ~48 months)
Pathological complete response (pCR)
pCR is defined as normal tumor markers and completely resected residual masses containing only necrosis or teratoma
Time frame: Time from enrollment to death due to any cause, or data cut-off date, whichever occurred first (up to ~60 months)
Adverse events
Safety per CTCAE v5.0.
Time frame: Time from enrollment to death due to any cause, or data cut-off date, whichever occurred first (up to ~60 months)
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Oct 2028, 48 months after the start.
Of 17 phase 2 interventional studies under Testicular Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 83. This study's planned 48 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paclitaxel
Blokhin's Russian Cancer Research Center